HK Stock Market Move | PEIJIA-B(09996) increased by nearly 7%, TaurusTrio aortic valve system officially approved in China.

PEIJIA-B (09996) rose nearly 7%, at the time of publication, it was up 6.88% to HKD 6.21, with a turnover of HKD 7.4878 million. On the news front, Peijia Medical announced that on December 11th, the company received approval from the National Medical Products Administration of the People's Republic of China for the registration application of the TaurusTrio Transcatheter Aortic Valve (TAV) System. The TaurusTrio TAV system was developed and manufactured by the company based on the exclusive license of the Trilogy Transcatheter Heart Valve (THV) system obtained from JenaValve Technology, Inc. (JenaValve). The announcement stated that JenaValve's Trilogy THV system received CE marking certification in May 2021, and as of the announcement date, it has been used in over 1000 commercial surgeries in real-world clinical practice. The company expects the TaurusTrio TAV system to be successfully launched in China, providing a safe and effective treatment option for Chinese patients with severe AR, thus meeting a significant unmet clinical need.